---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-024106"
form_type: "8-K/A"
ticker: "HRGN"
cik: "0001563665"
company_name: "Harvard Apparatus Regenerative Technology, Inc."
filed_at: "2023-07-10T23:59:59+00:00"
generated_at: "2026-06-13T10:34:36.789268+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Biostage reduces CEO milestone stock options from 488,256 to 267,616 shares

## Summary
- Amendment corrects Milestone Grant for CEO Junli He from 488,256 to 267,616 shares.
- Each vesting increment reduced from 244,128 to 133,808 shares, still two tranches.
- Effective retroactively to March 14, 2023; no other changes to employment agreement.
- Reduction lowers potential dilution from milestone options by approximately 45%.

## SEC filing metadata
- accession: 0001493152-23-024106
- form_type: 8-K/A
- ticker: HRGN
- cik: 0001563665
- company_name: Harvard Apparatus Regenerative Technology, Inc.
- filed_at: 2023-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563665/000149315223024106/0001493152-23-024106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563665/000149315223024106/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-024106
- JSON: https://secwatch.observer/filing/0001493152-23-024106.json
- Plain text: https://secwatch.observer/filing/0001493152-23-024106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.